MannKind discontinues Phase 3 MNKD-101 trial for NTM lung disease after futility analysis

MANNKIND CORP

Discontinuation based on interim analysis of first 46 participants; none showed sputum culture conversion.
DSMB agreed with decision due to futility; no safety issues identified in any DSMB meetings.
Company will investigate outcome and focus on advancing MNKD-102 dry powder formulation toward Phase 1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.